Volume 17, Issue 1 (8-2023)                   Qom Univ Med Sci J 2023, 17(1): 299-308 | Back to browse issues page

Research code: 51601901016001


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shaheli M, Yaghobi R, Ramzi M. Prevalence of Torque Teno Virus, Hepatitis and Cytomegalovirus Infection in Iranian Patients With Different Types of leukemia. Qom Univ Med Sci J 2023; 17 (1) : 2693.1
URL: http://journal.muq.ac.ir/article-1-3557-en.html
1- Department of Biology, Faculty of Basic Sciences, Arsanjan Branch, Islamic Azad University, Arsanjan, Iran. , Marjan.Shaheli@iau.ac.ir
2- Shiraz Transplant Research Center, Shiraz University of Medical Sciences,Shiraz, Iran.
3- Hematology and Bone Marrow Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Full-Text [PDF 3360 kb]   (485 Downloads)     |   Abstract (HTML)  (1330 Views)
Full-Text:   (517 Views)
Introduction
Human viruses may be involved in the initiation or progression of leukemia. Information and knowledge about the relationship between viral infections and the pathogenesis of hematologic malignancies is definitely limited. One of the viruses that may be related to the pathogenesis of various acute and chronic hematological malignancies is the Torque teno virus (TTV). This non-enveloped virus has a single-stranded circular DNA genome with a volume of 3.8 kilobases. The laboratory methods for diagnosis of TTV infection are still very primitive, because no tissue culture system has been found with sufficient sensitivity for isolation of TTV. Also, the immune responses to the virus are difficult to understand, and there is no easy serological method. The TTV infection can be seen in people with different types of leukemia and may affect clinical outcomes. This study aims to investigate the prevalence of TTV, hepatitis B and C virus, and cytomegalovirus (CMV) in Iranian patients with different types of leukemia.
Methods
In this descriptive cross-sectional study, blood samples containing ethylenediaminetetraacetic acid (EDTA) were collected from 95 patients with leukemia. The genomic DNA analysis of TTV was evaluated using the semi-nested PCR method. In the first PCR step, the total volume of the PCR mixture included 5-μL template DNA, 1 μL of each primer, 0.25-mM deoxynucleoside triphosphate, 1-μL Top DNA polymerase, 10-mM Tris-HCL, 30 mM KCl, 1.5-mM MgCl2, and 13 μL of distilled water. In the next step, 5 μl of the simple PCR product was used to perform a semi-nested process with the same conditions as the simple PCR mixture. The presence of HBs-Ag and HCV-Ab in patients was evaluated using the third-generation ELISA kit. Also, active cytomegalovirus infection was assessed in EDTA-containing whole blood samples collected from patients using the CMV kit. The significance of the molecular prevalence of TTV infection in patients was analyzed using logistic regression analysis, chi-square test, and Fisher’s exact test in SPSS software version 12. P≤0.05 level was considered as statistically significant.


Results
The mean age of patients was 20 years. Of 95 patients, 32 (33.7%) were female and 63 (66.3%) were male. The most common blood type was type B (27.8%). The TTV infection was confirmed in 40 out of 95 patients (42%). The HBsAg was observed in 27 out of 95 patients (28.4%), indicating hepatitis B virus (HBV) infection. Also, HCV-Ab was observed in 18 of 69 patients (26.1%), indicating hepatitis C virus (HCV) infection. A significant relationship was observed between age and TTV infection (P=0.007) and between chemotherapy regimen and TTV infection (P=0.003). Among 40 leukemia patients with TTV infection, 15 (37.5%) had also HBV infection, 14 (35%) had HCV infection, and 7 (17.5%) had CMV infection.
Conclusion
Previous studies have reported different prevalence rates of TTV infection in patients with leukemia, due to different liver involvements. The mechanism of TTV transmission has not yet been fully clarified, and the high prevalence of this virus in people treated with blood products indicates that transmission through blood is the most dangerous way of TTV transmission. The detection of the high prevalence of single and comorbid TTV infection in Iranian patients with leukemia emphasizes the importance of this virus in causing or aggravating the clinical outcomes of these patients, which should be investigated in the future studies. Many factors such as chromosomal defects, initial weakening of the immune system, environmental factors, exposure to high doses of radiation, and working in industrial areas, as well as genetic factors are involved in the development of leukemia.
Due to the possibility of the high infection rate of TTV in blood cells, especially the lymphocyte cell line, and the possible impact of this virus infection on the spread and occurrence of clinical complications in patients with leukemia, more studies are needed. The diagnosis of TTV infection in patients with all types of leukemia, which was done in this study for the first time, although indicated the high prevalence of TTV in these patients, it is necessary to check the past and present infection with this virus by serological methods to better suggest the prevalence rate. Other risk factors of leukemia should also be investigated. Since TTV was identified with high prevalence among Iranian people with leukemia, more studies and new techniques are needed to investigate the pathogenesis of this virus. It is also better to use bone marrow cells to screen this virus.
Ethical Considerations
Compliance with ethical guidelines
The procedures in study in this study were in accordance with the ethical guidelines and the Declaration of Helsinki.
Funding
This study was funded by Islamic Azad University, Arsanjan Branch.
Authors contributions
The authors contributed equally to preparing this article.
Conflicts of interest
The authors declare no conflict of interest.
Acknowledgments
The authors would like to thank all the patients participated in this study for their cooperation.
Type of Study: Original Article | Subject: میکروب شناسی
Received: 2022/08/28 | Accepted: 2022/09/26 | Published: 2023/08/1

References
1. Lawson JS, Salmons B, Glenn WK. Oncogenic viruses and breast cancer: Mouse mammary tumor virus (MMTV), bovine leukemia virus (BLV), human papilloma virus (HPV), and Epstein-barr virus (EBV). Front Oncol. 2018; 8:1. [DOI:10.3389/fonc.2018.00001] [PMID] [DOI:10.3389/fonc.2018.00001]
2. Leijonhufvud G, Bajalan A, Teixeira Soratto TA, Gustafsson B, Bogdanovic G, Bjerkner A, et al. Better detection of Torque teno virus in children with leukemia by metagenomic sequencing than by quantitative PCR. J Med Virol. 2022; 94(2):634-41. [DOI:10.1002/jmv.27409] [PMID] [DOI:10.1002/jmv.27409]
3. Chu CC, Zhang L, Dhayalan A, Agagnina BM, Magli AR, Fraher G, et al. Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera. Mol Med. 2011; 17(11-12):1338-48. [DOI:10.2119/molmed.2010.00110] [PMID] [DOI:10.2119/molmed.2010.00110]
4. Spandole S, Cimponeriu D, Berca LM, Mihăescu G. Human anelloviruses: An update of molecular, epidemiological and clinical aspects. Arch Virol. 2015; 160(4):893-908. [DOI:10.1007/s00705-015-2363-9] [PMID] [DOI:10.1007/s00705-015-2363-9]
5. Hino S, Miyata H. Torque teno virus (TTV): Current status. Rev Med Virol. 2007; 17(1):45-57. [DOI:10.1002/rmv.524] [PMID] [DOI:10.1002/rmv.524]
6. Shiramizu B, Yu Q, Hu N, Yanagihara R, Nerurkar VR. Investigation of TT virus in the etiology of pediatric acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2002; 19(8):543-51. [DOI:10.1080/08880010290097396] [PMID] [DOI:10.1080/08880010290097396]
7. Kulifaj D, Durgueil-Lariviere B, Meynier F, Munteanu E, Pichon N, Dubé M, et al. Development of a standardized real time PCR for Torque teno viruses (TTV) viral load detection and quantification: A new tool for immune monitoring. J Clin Virol. 2018; 105:118-27. [DOI:10.1016/j.jcv.2018.06.010] [PMID] [DOI:10.1016/j.jcv.2018.06.010]
8. Khudair EA, Al-Shuwaikh AM, Farhan NM. Detection of TTV antigen in patients with hepatitis HBV and HCV. Iraqi J Med Sci. 2019. 17(1):43-9. [DOI:10.22578/IJMS.17.1.7] [DOI:10.22578/IJMS.17.1.7]
9. Shaheli M, Yaghobi R, Rezaeian A, Iravani Saadi M, Ramzi M. Study of the associations between TT Virus single and mixed infections with leukemia. Jundishapur J Microbiol. 2015; 8(4):e18212. [DOI:10.5812/jjm.8(4)2015.18212] [DOI:10.5812/jjm.8(4)2015.18212]
10. Pradier A, Masouridi-Levrat S, Bosshard C, Dantin C, Vu DL, Zanella MC, et al. Torque teno virus as a potential biomarker for complications and survival after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020; 11:998. [DOI:10.3389/fimmu.2020.00998] [PMID] [DOI:10.3389/fimmu.2020.00998]
11. Reshetnyak VI, Maev IV, Burmistrov AI, Chekmazov IA, Karlovich TI. Torque teno virus in liver diseases: On the way towards unity of view. World J Gastroenterol. 2020; 26(15):1691-707. [DOI:10.3748/wjg.v26.i15.1691] [PMID] [PMCID] [DOI:10.3748/wjg.v26.i15.1691]
12. Pan S, Yu T, Wang Y, Lu R, Wang H, Xie Y, et al. Identification of a torque teno mini virus (TTMV) in hodgkin's lymphoma patients. Front Microbiol. 2018; 9:1680. [DOI:10.3389/fmicb.2018.01680] [PMID] [DOI:10.3389/fmicb.2018.01680]
13. Zhong S, Yeo W, Tang MW, Lin XR, Mo F, Ho WM, et al. Gross elevation of TT virus genome load in the peripheral blood mononuclear cells of cancer patients. Ann N Y Acad Sci. 2001; 945:84-92. [DOI:10.1111/j.1749-6632.2001.tb03868.x] [PMID] [DOI:10.1111/j.1749-6632.2001.tb03868.x]
14. Fanci R, De Santis R, Zakrzewska K, Paci C, Azzi A. Presence of TT virus DNA in bone marrow cells from hematologic patients. New Microbiol. 2004; 27(2):113-7. [PMID]
15. Maggi F, Focosi D, Albani M, Lanini L, Vatteroni ML, Petrini M, et al. Role of hematopoietic cells in the maintenance of chronic human torquetenovirus plasma viremia. J Virol. 2010; 84(13):6891-3. [DOI:10.1128/JVI.00273-10] [PMID] [DOI:10.1128/JVI.00273-10]
16. Schmitz J, Kobbe G, Kondakci M, Schuler E, Magorsch M, Adams O. The value of torque teno virus (TTV) as a marker for the degree of immunosuppression in adult patients after hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant. 2020; 26(4):643-50. [DOI:10.1016/j.bbmt.2019.11.002] [PMID] [DOI:10.1016/j.bbmt.2019.11.002]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Qom University of Medical Sciences Journal

Designed & Developed by : Yektaweb